Urgent.News

What's breaking now, across thousands of outlets.

Business

Eli Lilly is buying a biotech startup for nearly $3 billion to expand into autoimmune diseases

The deal adds a pipeline targeting the antibodies behind Graves' disease, thyroid eye disease, food allergy, and other conditions

Eli Lilly is buying a biotech startup for nearly $3 billion to expand into autoimmune diseases

We haven't written up this one. Quartz has the full story — the link below goes straight to it.

Read the original at qz.com →

More in Business

More from Monday 31 August →